In conclusion, the present study showed that elevated plasma levels of FGF23 pre-HT predicted an increase in lumbar BMD after HT, which may be partly explained by the complex pathophysiological mechanisms in relation to the comorbid burden and immunosuppressive therapy in this patient cohort. The gene discussed is FGF23; the disease is hematocrit.